Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Our management team and Board of Directors remain extremely dedicated to the overall success of the corporation. This is evidenced by every member working without cash consideration since Amarantus became public in the spring of 2011. This has allowed all available resources to be focused on product development."
I wonder what would cause these people to work without pay? Hmmm...
Very, very long AMBS
Email from CEO about financing:
From Yahoo.
"Hello **********,
I understand your concern. However, we do not feel it is appropriate to look at it this way. We have not actually diluted the shareholders. We have issued very minimal stock with this financing. If you look at the terms of the transaction, shares are to be issued at $0.10 on the convertible note and we have the ability to repay the note if we raise capital on better terms in the future.
I hope you can understand that not every decision is an easy one. The reality is that we weighed this decision very heavily and came up with the number in a very sobering manner so as to look at worse-case scenarios. Funding a multi-billion dollar potential drug candidate will likely take dilutive financings, and we are working to ensure that we raise the necessary funding on the best terms possible so as to ensure limited dilution. We are hopeful the market will respond positively to future developments and that we will be able to fund product development and ongoing operations on the best terms possible so as to minimize dilution. We planned for the worse, but certainly are working to make sure the best possible outcome is achieved for our shareholders.
Best Regards,
Gerald"
Seeking Alpha article Finding a Cure for Parkinson's dated 11/18/12:
http://seekingalpha.com/article/1016221-finding-a-cure-for-parkinson-s?source=feed
Could not get link from previous post to work.
Very, very long AMBS
9.5 M traded from 930 - 11 A. 4.3 M traded from 11 A to now. The PPS has been basically the same since 11 A. I wouldn't call that bailing or losing confidence. I'd call that the normal lunch time malaise.
Very, very long AMBS
According to news on the company website, he was added to the Corporate Advisory Board. Both he and Clinton Allen are now listed in the ibox under Advisory Board. If and when we get clarification from the company, I will update accordingly.
Very, very long AMBS
"We are at a very exciting time here at Amarantus. We have secured the resources and advisors to advance our current assets and expand our business development efforts. We will implement this strategy by honing in on our core program, MANF, and finding innovative solutions to further enable MANF's development and secure Amarantus' ownership of the MANF space. We are encouraged by our data to date, and continue to believe the asset has blockbuster potential.
Your Board of Directors and management team remain dedicated to improving the lives of patients suffering from a variety of illnesses and diseases. We are motivated by the prospects of the company, and our primary focus remains: progressing our assets to help patients and increase shareholder value. I would like to personally thank each of you, and will work to ensure your trust is maintained as Amarantus grows."
Very, very long AMBS
"Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction. We are evaluating the possibilities of the MANF program in various orphan disease areas through our recent grant from the Center of Excellence for Apoptosis Research and collaborations with academic labs. We expect this process to be completed within a calendar year, and we will be updating shareholders on an on-going basis regarding results of experiments as data becomes available. The key advantage to this strategy is that the Investigational New Drug (IND) protocols required for our Parkinson's program will overlap with our orphan drug program; therefore, an additional IND should be attainable in the same timeframe."
Very very long AMBS
CEO Update dated 11/19/12.
http://www.prnewswire.com/news-releases/amarantus-biosciences-issues-ceo-letter-to-shareholders-179929151.html
Looking for 10-Q prior to market open.
Very, very long AMBS
Originally posted 11/14/12 by ID Supermoney:
LymPro has completed two human clinical studies to date, and is set to move immediately into the Phase 2 validation study required to begin generating revenue as a laboratory developed test ("LDT") at an already-selected Certified Laboratory Improvement Amendments ("CLIA") certified laboratory. Thereafter, we anticipate LymPro will begin its regulatory process with the Food and Drug Administration towards approval
Money coming in shortly!!
Originally posted 11/14/12 by Disney714:
Check off the list
May 7, 2012
The most critical milestones for us to achieve in the next 12 months are:
1. Raising sufficient capital to efficiently fund our therapeutic and diagnostic programs
a) PENSCO Trust Co. FBO Robert L. Harris lent us the principal sum of $50,000
b) Awarded a Translational Research Grant award from the University of Massachusetts' Pioneer Valley Life Sciences Institute's Center of Excellence in Apoptosis Research (CEAR)
c) Dr. Joseph Rubinfeld, co-founder of Amgen bought 1,000,000 shares
2. Advancing our various product development programs to key value inflexion milestones
a) Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
b) Secured the license for the NuroPro Parkinson's diagnostic blood test; and
c) Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
d) Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test
e) Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
Next: Analyzing, processing and submitting data from the Company’s ongoing animal experiments comparing MANF and GDNF to the Michael J. Fox Foundation, to be completed within 45 days;
Next: Completing the recruiting of the scientific team required to re-validate Phase 1 clinical data of the Company’s NuroPro Parkinson’s Disease Blood Test, to be completed within 30 days;
3. Finalizing the business development transactions executed over the past 12 months
a) Amarantus BioSciences Secures $1.1 Million in Financing
4. Recruiting seasoned product development expertise in the areas of biopharmaceutical and diagnostic product development
a) Amarantus BioSciences Appoints Clinton O. Allen To Advisory Board
b) Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
c) Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
Next: Completing the recruiting of certain key seasoned biopharmaceutical executives to the Company’s management team and Board of Directors, to be completed within 15 days;
Just to close the loop on the $ details of the MJFF grant:
$192,408 received FY 2010
$178,308 received FY 2011
Total grant $370,716
Extracted from FY 2011 10-K dtd 4/20/12.
Amarantus' potential is so much greater than most can comprehend, and quibbling over a few pennies at this stage is going to be so unimportant in the coming months and years to INVESTORS.
Very, very long AMBS
Here is what I asked for in my post #11687:
"Do you have proof that the company PAID FOR the promotions? The several I saw stated paid for by a third party. With the constant manipulation in the markets, I can think of any number of other parties who would gladly pay for a promotion."
Also, manipulation by groups is a constant in penny stocks, and AMBS has certainly had its share recently. However, this company is no stinky pinkie, though mentalities sometimes have a hard time differentiating from real companies and "penny" companies.
Real company, real products, real quality people.
Very, very long AMBS
President & CEO Gerald E. Commissiong expects to update shareholders regarding corporate development plans and strategies going forward for Amarantus following the release of the Company's quarterly financial report, expected early this week.
Very, very long AMBS
MANF to go for orphan drug status.
Potential multi-billion dollar company in the making:
1) First test ever for Parkinsonism.
2) First test ever for Alzheimers disease.
3) Possible drug to cure Parkinsonism.
4) Drug to HEAL heart damage maybe up to 40% in heart attack victums.
5) Possible drug to heal stroke victims.
6) Dr. David Rubinfeld, Amgen Co Founder states, "I believe in MANF. I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Very, very long AMBS
Originally posted by BabyFreshNuggz on 11/7/12:
This AMBS interview is one of the more professional explanations I have ever seen for a stock. This is actually not going to be below $1 for very long. This company is clearly meant for greater things.
AMBS NEW INVESTOR RELATIONS INTERVIEW W/ CEO Gerald E. Commissiong. Explains whats happening.. LINK- http://www.amarantus.com/investor-relations/videos.html
Do you have proof that the company PAID FOR the promotions? The several I saw stated paid for by a third party. With the constant manipulation in the markets, I can think of any number of other parties who would gladly pay for a promotion.
Very, very long AMBS
CNS Tweet.
CNSSummit Packed room for Sunday morning sessions w/presentations by pharma cos. Everyone very attentive.
Very, very long AMBS
MANF: A Two-Domain Neurotrophic Factor with Multiple Indications
John Commissiong
CSO, Amarantus Biosciences, Inc.
John's topic for today.
Very, very long AMBS
As a long-term investor, I have minimal interest in this 10-Q except that it serves to keep AMBS current on financials.
To me, the:
1) forthcoming CEO's shareholder update,
2) growing list of "major players" (and I'm NOT talking about ihub personalities) involved,
3) science and results,
4) broad-based applications and
5) extreme potential
make this a no brainer in my portfolio.
Very, very long AMBS
Just to close the loop on the $ details of the MJFF grant:
$192,408 received FY 2010
$178,308 received FY 2011
Total grant $370,716
Extracted from FY 2011 10-K dtd 4/20/12.
Amarantus' potential is so much greater than most can comprehend, and quibbling over a few pennies at this stage is going to be so unimportant in the coming months and years to INVESTORS.
Very, very long AMBS
Originally posted 11/14/12 by Disney714:
Check off the list
May 7, 2012
The most critical milestones for us to achieve in the next 12 months are:
1. Raising sufficient capital to efficiently fund our therapeutic and diagnostic programs
a) PENSCO Trust Co. FBO Robert L. Harris lent us the principal sum of $50,000
b) Awarded a Translational Research Grant award from the University of Massachusetts' Pioneer Valley Life Sciences Institute's Center of Excellence in Apoptosis Research (CEAR)
c) Dr. Joseph Rubinfeld, co-founder of Amgen bought 1,000,000 shares
2. Advancing our various product development programs to key value inflexion milestones
a) Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
b) Secured the license for the NuroPro Parkinson's diagnostic blood test; and
c) Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
d) Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test
e) Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
Next: Analyzing, processing and submitting data from the Company’s ongoing animal experiments comparing MANF and GDNF to the Michael J. Fox Foundation, to be completed within 45 days;
Next: Completing the recruiting of the scientific team required to re-validate Phase 1 clinical data of the Company’s NuroPro Parkinson’s Disease Blood Test, to be completed within 30 days;
3. Finalizing the business development transactions executed over the past 12 months
a) Amarantus BioSciences Secures $1.1 Million in Financing
4. Recruiting seasoned product development expertise in the areas of biopharmaceutical and diagnostic product development
a) Amarantus BioSciences Appoints Clinton O. Allen To Advisory Board
b) Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
c) Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
Next: Completing the recruiting of certain key seasoned biopharmaceutical executives to the Company’s management team and Board of Directors, to be completed within 15 days;
Originally posted 11/14/12 by ID Supermoney:
LymPro has completed two human clinical studies to date, and is set to move immediately into the Phase 2 validation study required to begin generating revenue as a laboratory developed test ("LDT") at an already-selected Certified Laboratory Improvement Amendments ("CLIA") certified laboratory. Thereafter, we anticipate LymPro will begin its regulatory process with the Food and Drug Administration towards approval
Money coming in shortly!!
Originally posted 11/16/12 by Disney714:
From one of CNS SUMMIT 2011 Slides
What worked?
22 programs.
100% utilized new mechanisms
2 discovered by Big Pharma
20 discovered by small companies:
2 were partnered in discovery stage
1 was partnered in preclinical stage
4 were partnered in Phase II
12 were partnered in Phase III
1 will be marketed in US by the originator and not partnered
Of the 12 partnered in Phase III, all would have had their timelines significantly reduced if partnering had occurred earlier.
Just a thought: Present Scientific Data, Partnerships/Buyouts
Thanks! I stickied for quick reference.
Very, very long AMBS
ihub L2 shows it as green which normally would signify at the ask.
Originally posted 11/16/12 by Disney714:
From one of CNS SUMMIT 2011 Slides
What worked?
22 programs.
100% utilized new mechanisms
2 discovered by Big Pharma
20 discovered by small companies:
2 were partnered in discovery stage
1 was partnered in preclinical stage
4 were partnered in Phase II
12 were partnered in Phase III
1 will be marketed in US by the originator and not partnered
Of the 12 partnered in Phase III, all would have had their timelines significantly reduced if partnering had occurred earlier.
Just a thought: Present Scientific Data, Partnerships/Buyouts
This week starts what we believers have been anticipating for a while.
VERY, VERY LONG AMBS
Originally posted 11/14/12 by ID Supermoney:
LymPro has completed two human clinical studies to date, and is set to move immediately into the Phase 2 validation study required to begin generating revenue as a laboratory developed test ("LDT") at an already-selected Certified Laboratory Improvement Amendments ("CLIA") certified laboratory. Thereafter, we anticipate LymPro will begin its regulatory process with the Food and Drug Administration towards approval
Money coming in shortly!!
Originally posted 11/14/12 by Disney714:
Check off the list
May 7, 2012
The most critical milestones for us to achieve in the next 12 months are:
1. Raising sufficient capital to efficiently fund our therapeutic and diagnostic programs
a) PENSCO Trust Co. FBO Robert L. Harris lent us the principal sum of $50,000
b) Awarded a Translational Research Grant award from the University of Massachusetts' Pioneer Valley Life Sciences Institute's Center of Excellence in Apoptosis Research (CEAR)
c) Dr. Joseph Rubinfeld, co-founder of Amgen bought 1,000,000 shares
2. Advancing our various product development programs to key value inflexion milestones
a) Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
b) Secured the license for the NuroPro Parkinson's diagnostic blood test; and
c) Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
d) Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test
e) Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
Next: Analyzing, processing and submitting data from the Company’s ongoing animal experiments comparing MANF and GDNF to the Michael J. Fox Foundation, to be completed within 45 days;
Next: Completing the recruiting of the scientific team required to re-validate Phase 1 clinical data of the Company’s NuroPro Parkinson’s Disease Blood Test, to be completed within 30 days;
3. Finalizing the business development transactions executed over the past 12 months
a) Amarantus BioSciences Secures $1.1 Million in Financing
4. Recruiting seasoned product development expertise in the areas of biopharmaceutical and diagnostic product development
a) Amarantus BioSciences Appoints Clinton O. Allen To Advisory Board
b) Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
c) Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
Next: Completing the recruiting of certain key seasoned biopharmaceutical executives to the Company’s management team and Board of Directors, to be completed within 15 days;
$AMBS~Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test:
http://finance.yahoo.com/news/amarantus-biosciences-acquires-option-license-110000588.html
Very long AMBS
Just to close the loop on the $ details of the MJFF grant:
$192,408 received FY 2010
$178,308 received FY 2011
Total grant $370,716
Extracted from FY 2011 10-K dtd 4/20/12.
Amarantus' potential is so much greater than most can comprehend, and quibbling over a few pennies at this stage is going to be so unimportant in the coming months and years to INVESTORS.
Very long AMBS
AMBS' Chief Scientific Officer John W. Commissiong, PhD, has been invited to make a presentation to discuss "MANF as therapeutic for Parkinson's disease" at the Scientific Session of the CNS Summit 2012 in Boca Raton, FL on Sunday, November 18th, 2012. CNS Summit 2012 is a community that has come together with the goal of collaborating and innovating to bring new treatments to patients suffering from brain disorders.
Very long AMBS
They just know and believe in what they now own. Potential beyond the understanding of most on ihub.
Very long AMBS
I believe his shareholder update is going to prove so much more important.
Very long AMBS
This 10Q is nothing more than a formality for this company. So much potential.
Very long AMBS
AMBS is so far beyond the manipulation of the "stinky pinkie personalities." What we see here is just a small piece of the bigger investor/shareholder picture.
Very long AMBS
Those will be some very expensive drinks they are rushing out for.
Very long AMBS
Yes they most certainly will.
Very long AMBS
Since 1:30, 1.4 M walkdown by traders leaving before weekend.
Very long AMBS